广济药业：拟对全资子公司减资2200万元

Core Viewpoint - Guangji Pharmaceutical announced a capital reduction of 22 million yuan for its wholly-owned subsidiary, the Biological Research Institute, as part of its strategic planning to optimize asset structure and improve management efficiency [1] Financial Performance - The Biological Research Institute's revenue for the first nine months of 2025 was 2.3585 million yuan, with a net loss of 1.3102 million yuan [1] - In 2024, the revenue was 599,100 yuan, with a net loss of 5.7612 million yuan [1] Capital Structure - Prior to the capital reduction, the registered capital of the Biological Research Institute was 50 million yuan, which will be reduced to 28 million yuan [1] - The company will maintain a 100% ownership stake in the Biological Research Institute, and the capital reduction will not affect the consolidated financial statements [1]